Clinical Trials Conditions Microdosing Pharmaceutical 
The Joint Blog
NOVEMBER 15, 2021
While over the last few years, microdosing has become extremely popular, the act of microdosing has been recommended by experts for at least two decades. There are also many different substances that you can microdose, from psilocybin mushrooms to delta-8. In this article, we are going to cover microdose of legal substances.
Cannabis Law Report
JUNE 19, 2022
Unlike novel chemical compounds that are synthetically produced in the pharmaceutical industry through drug development programs, psychedelic compounds have a long and established history. As we see more data emerge from clinical trials, we are likely to see patent applications covering stability, pharmacokinetic, and pharmacodynamic data.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Canna Law Blog
NOVEMBER 27, 2021
Notwithstanding its dubious distinction as a Schedule I drug, DMT increasingly is the subject of study for its potential efficacy in treating a wide array of mental-health conditions including depression, anxiety, and PTSD. Several months ago, Canada-based Algernon Pharmaceuticals submitted a request to U.S.
The Cannigma
JUNE 24, 2021
While many health conditions can be treated with more traditional pharmaceuticals, plant-based products may be a safer and healthier option – or at least a safe health supplement. These natural alternatives may also be effective as part of a daily “microdosing” regiment. Part of a natural, alternative lifestyle.
Cannabis Law Report
FEBRUARY 9, 2022
There’s also concern about a rare condition known as wood lover’s paralysis , a condition that produces muscle weakness a few hours after hallucinogenic mushrooms are consumed. Scientists don’t know why this condition occurs, but it isn’t believed to happen with Psilocybe cubensis. Other species might be introduced later.
Cannabis Law Report
MARCH 3, 2022
The team at Microdose, the world’s biggest medical psychedelic conference , said the country’s move to permit Med Plant Science Ltd to produce psychedelic compounds makes it the first country to legalize all psychedelic medicine. . The eventual trials would target PTSD, addiction, alcoholism, depression, and anxiety. and Europe.
Cannabis Law Report
SEPTEMBER 10, 2019
Forbes reported on Hopkins researchers’ recommendation that, if psilocybin should clear Phase III clinical trials, the FDA should reclassify it from a Schedule I to a Schedule IV drug. Schedule I drugs have no accepted medical use, while Schedule IV drugs include pharmaceuticals such as benzodiazepines.
Expert insights. Personalized for you.
49 
Let's personalize your content